aTyr Pharma

aTyr Pharma is developing novel therapeutics based on a new class of proteins called Physiocrines. The company’s programs are currently focused on severe, rare diseases characterized by immune dysregulation, for which there are currently limited or no treatment options. aTyr was founded by two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. Deerfield participated in a $75M Series E.